TG Therapeutics Inc. (TGTX) was among the biggest gainers on the Russell 2000 for Thursday January 14 as the stock popped 10.63% to $9.37, representing a gain of $0.9 per share. Some 446,357 shares traded hands on 4,105 trades, compared with an average daily volume of 610,874 shares out of a total float of 52.52 million. The stock opened at $8.49 and traded with an intraday range of $9.37 to $8.37.
After today's gains, TG Therapeutics Inc. reached a market cap of $492.11 million. TG Therapeutics Inc. has had a trading range between $20.00 and $7.68 over the last year, and it had a 50-day SMA of $12.14 and a 200-day SMA of $14.26.
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of medically important pharmaceutical products for the treatment of cancer & other underserved therapeutic needs.
TG Therapeutics Inc. is based out of New York, NY and has some 30 employees. Its CEO is Michael S. Weiss.
For a complete fundamental analysis analysis of TG Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for TGTX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.